Journal
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 15, Issue 2, Pages 131-144Publisher
SHENYANG PHARMACEUTICAL UNIV
DOI: 10.1016/j.ajps.2019.09.002
Keywords
Solute carrier transporter; Brain disorder; Blood-brain barrier; Drug
Categories
Funding
- Nation Science and Technology Major Projects for Major New Drugs Innovation and Development [2018ZX09711003-004-002]
- Ministry of Science and Technology of China National Key RD Programs [2018YFA0506903]
- National Natural Science Foundation of China [91857108]
Ask authors/readers for more resources
Solute carriers (SLCs) are the largest family of transmembrane transporters that determine the exchange of various substances, including nutrients, ions, metabolites, and drugs across biological membranes. To date, the presence of about 287 SLC genes have been identified in the brain, among which mutations or the resultant dysfunctions of 71 SLC genes have been reported to be correlated with human brain disorders. Although increasing interest in SLCs have focused on drug development, SLCs are currently still under-explored as drug targets, especially in the brain. We summarize the main substrates and functions of SLCs that are expressed in the brain, with an emphasis on selected SLCs that are important physiologically, pathologically, and pharmacologically in the blood-brain barrier, astrocytes, and neurons. Evidence suggests that a fraction of SLCs are regulated along with the occurrences of brain disorders, among which epilepsy, neurodegenerative diseases, and autism are representative. Given the review of SLCs involved in the onset and procession of brain disorders, we hope these SLCs will be screened as promising drug targets to improve drug delivery to the brain. (C) 2019 Shenyang Pharmaceutical University. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available